Skip to main content

Advertisement

SpringerLink
Log in

Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial

  • Original Article
  • Published:
Modern Rheumatology

Abstract

Objectives

To investigate the efficacy and safety of iguratimod (T-614) in Japanese patients with active rheumatoid arthritis who had inadequate response to stable background methotrexate (MTX) alone.

Methods

In this multicenter, double-blind, controlled trial, a total of 253 patients were randomized at 2:1 ratio to either the iguratimod group or the placebo group. Iguratimod was orally administered at dosages of 25 mg/day for the first 4 weeks (25 mg once daily) and 50 mg/day for the subsequent 20 weeks (25 mg twice daily). MTX at dosage of 6 or 8 mg/week was administered to patients in both groups.

Results

The rate of 20 % improvement in American College of Rheumatology criteria (ACR20) at week 24 was 69.5 % in the iguratimod group compared with 30.7 % in the placebo group (P < 0.001). Significant improvements in the ACR50, ACR70, Health Assessment Questionnaire Disability Index, Disease Activity Score 28 <3.2, and rheumatoid factor were also observed. The most commonly reported adverse events (AEs) were blood iron decrease, nasopharyngitis, and lymphocyte decrease. These AEs were mild or moderate in severity. No deaths occurred.

Conclusion

The study results suggest that iguratimod in combination with MTX was efficacious and had a manageable safety profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Baranauskaite A, Raffayová H, Kungurov N, Kubanova A, Venalis A, Helmle L, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2011. (Epub ahead of print).

  2. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2011 (Epub ahead of print).

  3. Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis. 2007;66:235–41.

    Article  PubMed  CAS  Google Scholar 

  4. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137:726–33.

    Article  PubMed  CAS  Google Scholar 

  5. Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol. 2005;15:323–8.

    Article  PubMed  CAS  Google Scholar 

  6. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology.American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.

    Google Scholar 

  7. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011;13(Suppl 1):S5.

    PubMed  CAS  Google Scholar 

  8. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol. 2007;17:1–9.

    Article  PubMed  Google Scholar 

  9. Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A, et al. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med. 1999;133:566–74.

    Article  PubMed  CAS  Google Scholar 

  10. Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol. 2001;28:2591–6.

    PubMed  CAS  Google Scholar 

  11. Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res. 2002;51:188–94.

    Article  PubMed  CAS  Google Scholar 

  12. Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology. 2003;42:1365–71.

    Article  PubMed  CAS  Google Scholar 

  13. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis. Mod Rheumatol. 2007;17:10–6.

    Article  PubMed  Google Scholar 

  14. Lu LJ, Bao CD, Dai M, Teng JL, Fan W, Du F, et al. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum. 2009;61:979–87.

    Article  PubMed  CAS  Google Scholar 

  15. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65:168–73.

    PubMed  Google Scholar 

  16. Chan ES, Cronstein BN. Methotrexate—how does it really work? Nat Rev Rheumatol. 2010;6:175–8.

    Article  PubMed  CAS  Google Scholar 

  17. Akkari R, Burbiel JC, Hockemeyer J, Müller CE. Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr Top Med Chem. 2006;6(13):1375–99.

    Article  PubMed  CAS  Google Scholar 

  18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.

    Article  PubMed  CAS  Google Scholar 

  19. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–35.

    Article  PubMed  CAS  Google Scholar 

  20. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9:789–93.

    PubMed  CAS  Google Scholar 

  21. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, Van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.

    Article  PubMed  CAS  Google Scholar 

  22. Fransen J, van Riel PL. Outcome measures in inflammatory rheumatic diseases. Arthritis Res Ther. 2009;11(5):244.

    Article  PubMed  Google Scholar 

  23. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43:1478–87.

    Article  PubMed  CAS  Google Scholar 

  24. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63:1150–8.

    Article  CAS  Google Scholar 

  25. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7.

    Article  PubMed  Google Scholar 

  26. Bridges SL. Update on autoantibodies in rheumatoid arthritis. Curr Rheumatol Rep. 2004;6:343–50.

    Article  PubMed  Google Scholar 

  27. Chaiamnuay S, Bridges SL Jr. The role of B cells and autoantibodies in rheumatoid arthritis. Pathophysiology. 2005;12:203–16.

    Article  PubMed  CAS  Google Scholar 

  28. Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loët X, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011;63:933–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to thank all the collaborating members of the Iguratimod-Clinical Study Group. Principal investigators and institutions were as follows: Kou Katayama (Katayama Orthopedic Rheumatology Clinic), Naoichiro Yukawa (Kyoto University Hospital), Satoshi Soen (Nara Hospital, Kinki University School of Medicine), Katsumi Eguchi, Atsushi Kawakami (Nagasaki University Hospital), Shuji Ohno (Ohno Clinic), Tomohiko Yoshida (Setagaya Rheumatology Center, Internal Medicine Department Yoshida Clinic), Takaaki Fukuda (Kurume University Medical Center), Keisuke Hashimoto (Hashimoto Clinic for Orthopedic or Rheumatic Diseases), Takashi Sato (Association of Medical Corporation Dainohara Orthopedic Surgery), Yuichi Takahashi (Yu Family Clinic), Eiji Sugiyama (Hiroshima University Hospital), Kenji Kohriyama (Shinsuma Hospital), Yasuhiko Munakata (Medical Corporation Biei Taihaku Sakura Hospital), Koichi Kitamura (Hakodate Goryokaku Hospital), Kanzo Amano (Hiroshima Clinic), Shigeo Miyashima (Miyashima RA and Orthopaedic Clinic), Akira Sagawa (Sagawa Akira Rheumatology Clinic), Takeo Sakurai (Inoue Hospital), Hiroo Yamane (Toyooka-daiichi Hospital), Wataru Hirose (Hirose Clinic), Hiroshi Nakashima (Nakajima Orthopaedic Surgery), Tamami Yoshitama (Yoshitama Clinic Rheumatology and Internal Medicine), Koichi Hirota (Hirota Medical Clinic), Motohide Kaneko (Kaneko Internal Medicine Rheumatology Clinic), Kunio Matsuta (Matsuta Clinic), Atsushi Fujisaku (Tomakomai City Hospital), Masanobu Mine (Suga Orthopedic Hospital), Shintaro Yano (Sanyakai Medical Corporation Maebashi Hirosegawa Clinic), Ichiro Oki (Oki Medical Clinic), Tatsumi Chijiwa (Medical Corporation Takatakai Kochi-Kinen Hospital), Masaya Mukai (Sapporo City General Hospital), Kazutoshi Aoki (Saitama Social Insurance Hospital), Munetoshi Nakashima (The Japanese Red Cross Nagasaki Genbaku Hospital), Jun Kishi (Tokushima University Hospital), Toshihisa Kanamono (Nagano Red Cross Hospital), Shuji Ohta (Taga General Hospital), Toshiaki Tsukada (Isehaya Health Insurance General Hospital), Yukitaka Ueki (Sasebo Chuo Hospital), Seiji Tsuboi (Shizuoka Kousei Hospital), Hirobumi Takahashi (Takahashi Medical Clinic), Hiroki Tsuchiya (Nagoya Kyoritsu Clinic), Tomomasa Izumiyama (Higashisendai Rheumatology Medical Clinic), Yukiyoshi Oishi, Yuji Hirano (Toyohashi Municipal Hospital), Takefumi Kato (Medical Corporation Kato Orthopedic Surgery), Shinichi Yamaguchi (Yamaguchi Clinic), Takanori Nagamine (Nagamine Orthopedic Clinic), Isao Furugo (JR Kyushu Hospital), Yasutaka Takagi (Tonami General Hospital), Takayuki Sumida (Tsukuba University Hospital), Ryosuke Kanda (Kitasenzoku Orthopedic Clinic), Keiji Maeda (NTT West Osaka Hospital), Tomomi Tsuru (Medical Co.LTA PS Clinic), Masakazu Kondo (Kondo Clinic of Rheumatology and Orthopaedic Surgery), Masatoshi Naito (Fukuoka University Hospital), Makoto Nishinarita (Nishinarita Clinic Office), Masakazu Nagashima (Tokyo Metropolitan Bokutoh Hospital), Hiroyuki Miyake (Ichinomiya Municipal Hospital), Takehiko Ayabe (Ayabe Clinic), Hideki Amma (Social Insurance Chukyo Hospital), Takeshi Oguchi (Anjo Kosei Hospital), Mitsugu Takahashi (Takahashi Orthopedics Clinic), Hiroshi Morio, Masaki Hiraguri (Japanese Red Cross Narita Hospital), Minoru Kurihara (Funaboriekimaeseikeigekanaika), Haruhiko Matsumoto (Munehiro Hospital), Juhro Fujimori (The Hofu Clinic for Orthopaedics and Rheumatology), Hiroshi Tsurukami (Tsurukami Clinic of Orthopedic and Rheumatology), Hiroshi Nakamura (Nakamura Orthopedic Clinic), Akio Suda (Suda Memorial Orthopedic Clinic), Hiroyuki Hagiyama (Yokohama City Minato Red Cross Hospital), Akikatsu Nakashima (Ishikawa-ken Saiseikai Kanazawa Hospital), Teiji Kontani (Komatsu Municipal Hospital), Shigeru Kamei (Kamei Orthopaedics), Takashi Maruyama (Yaenosato Hospital), Fumio Shinomiya (Centre for Rheumatic Disease, Mima Hospital in Yoshinogawa City), Seiji Yoshizawa (Hamanomachi Hospital), Kazuhide Tanimura (Hokkaido Medical Center for Rheumatic Diseases), Koji Hashimoto (Yamauchi Hospital), Hajime Kawamura (Kawamura Medical Clinic), Hiroyuki Nara (Kokubunji Sakura Clinic), Hidetomo Sato (Nasu Kogen Clinic), Shigeki Hidaka (Hidaka Orthopedic Hospital), Kenichi Murase (Nishikasai South Gate Department of Orthopedic Surgery and Rheumatology CL), Minoru Irahara (Irahara Clinic), Sadamu Suzuki (Suzuki Clinic), Makoto Kawakami (Tamatsukuri Kosei-Nenkin Hospital), Eisuke Shono (Shono Rheumatology Clinic), Junichi Obata (Hikarichuo Clinic), Motohiro Oribe (Oribe Clinic of Rheumatism and Medicine), Shoji Uchida (Uchida Clinic), Masao Nakajima (Kasumigaseki Urban Clinic), Takuya Sawabe (Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital), Koichiro Ishikawa (Ishikawa Orthopaedic and Rheumatism Hospital), Shin Munesada (Asunaro Orthopedic Clinic), Takashi Ohira (Ohira Orthopedic Hospital), Masaaki Yoshida (Yoshida Orthopedic Rheumatology Clinic), Tsukasa Matsubara (Matsubara Mayflower Hospital, Association of the Medical Corporation of Matsubara Clinic), Shigeru Honjo (Honjo Rheumatism Clinic), and Yuji Yamanishi (Hiroshima Rheumatology Clinic).

Conflict of interest

N.I. has received speakers bureau from Abbott Japan Co., Ltd., Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Kaken Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Taisho Toyama Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd. K.Y. has received grant and research support from Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., and Santen Pharmaceutical Co., Ltd.; speakers bureau from Abbott Japan Co., Ltd., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Santen Pharmaceutical Co., Ltd. M.K. has received speakers bureau from Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Pfizer Japan Inc. T.S. has received grant and research support from Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Pfizer Japan Inc.; speakers bureau from Abbott Japan Co., Ltd., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Santen Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd. T.M. has received grant and research support from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., Santen Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd.; speakers bureau from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., Santen Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd. S.S. has received grant and research support from Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., Sanofi Aventis K.K., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Limited; speakers bureau from Astellas Pharma Inc., Bristol-Myers Squibb K.K., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd. K.N. is an employee of Eisai Co., Ltd. T.Y. is an employee of Toyama Chemical Co., Ltd. N.I., K.Y., K.K., M.K., T.S., T.M., S.S., and M.H. served for consultancy to Eisai Co., Ltd. and Toyama Chemical Co., Ltd.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan

    Naoki Ishiguro

  2. Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    Kazuhiko Yamamoto

  3. Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan

    Kou Katayama

  4. Kondo Clinic of Rheumatology and Orthopaedic Surgery, Fukuoka, Japan

    Masakazu Kondo

  5. Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Takayuki Sumida

  6. Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Tsuneyo Mimori

  7. Department of Orthopaedic Surgery and Rheumatology, Nara Hospital, Kinki University School of Medicine, Ikoma, Japan

    Satoshi Soen

  8. Eisai Co., Ltd, Tokyo, Japan

    Kota Nagai

  9. Toyama Chemical Co., Ltd, Tokyo, Japan

    Tomonobu Yamaguchi

  10. Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Masako Hara

Authors
  1. Naoki Ishiguro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhiko Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kou Katayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masakazu Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takayuki Sumida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tsuneyo Mimori
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Satoshi Soen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kota Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomonobu Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masako Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Iguratimod-Clinical Study Group

Corresponding author

Correspondence to Naoki Ishiguro.

About this article

Cite this article

Ishiguro, N., Yamamoto, K., Katayama, K. et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 23, 430–439 (2013). https://doi.org/10.1007/s10165-012-0724-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-012-0724-8

Keywords

Search

Navigation